Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Anaptysbio Inc (NQ: ANAB ) 22.28 +0.65 (+3.01%) Streaming Delayed Price Updated: 1:47 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Anaptysbio Inc < Previous 1 2 3 Next > 12 Health Care Stocks Moving In Wednesday's Intraday Session October 30, 2024 Via Benzinga O-I Glass Posts Downbeat Results, Joins AMD, Qorvo And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session October 30, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session October 30, 2024 Via Benzinga A Glimpse Into The Expert Outlook On AnaptysBio Through 6 Analysts October 21, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session September 30, 2024 Via Benzinga What Analysts Are Saying About AnaptysBio Stock September 26, 2024 Via Benzinga Insiders Buying Yum China And 2 Other Stocks August 19, 2024 Via Benzinga Why AnaptysBio Was Such a Healthy Stock This Week August 23, 2024 The company's immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor. Via The Motley Fool UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday August 14, 2024 Via Benzinga AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering August 14, 2024 The company is working on treatments for immunological diseases, including eczema and rheumatoid arthritis. Via Investor's Business Daily S&P 500 Rises, Small Caps Outperform As July Consumer Price Index Fuels Fed Rate Cut Hopes: 5 ETFs to Watch Wednesday August 14, 2024 US inflation eases in July, keeping Fed rate cut hopes alive. Stocks rise, yields stable, dollar gains against yen. Tech and small caps outperform. Via Benzinga Topics ETFs Economy Stocks Exposures Interest Rates US Equities 4 Analysts Assess AnaptysBio: What You Need To Know August 06, 2024 Via Benzinga The Analyst Landscape: 7 Takes On AnaptysBio May 10, 2024 Via Benzinga Unveiling 4 Analyst Insights On AnaptysBio April 01, 2024 Via Benzinga ANAB Stock Earnings: AnaptysBio Misses EPS, Misses Revenue for Q2 2024 August 05, 2024 ANAB stock results show that AnaptysBio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. Via InvestorPlace AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst July 22, 2024 HC Wainwright initiated coverage on AnaptysBio with a Buy rating and a $55 price target. AnaptysBio focuses on immunology therapeutics with a promising pipeline. Via Benzinga ANAB Stock Earnings: AnaptysBio Misses EPS, Beats Revenue for Q1 2024 May 09, 2024 ANAB stock results show that AnaptysBio missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. Via InvestorPlace BTIG Research Predicts Over 118% Rally for These 3 Stocks April 15, 2024 Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money. Via InvestorPlace Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week April 12, 2024 A powerfully bullish new analyst take on the company helped it rally on the market. Via The Motley Fool Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session April 11, 2024 Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. Via Benzinga Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday April 11, 2024 U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session. Via Benzinga Topics Stocks Exposures US Equities Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers March 12, 2024 AnaptysBio exceeds Q4 2023 earnings expectations, with sales of $9.01 million. Expectations high post-Wedbush upgrade, foreseeing stock surge amid clinical milestones. Analysis compares PD-1 agonist... Via Benzinga Why Is Skin Disease Focused AnaptysBio Stock Trading Higher Today? October 09, 2023 AnaptysBio Inc (NASDAQ: ANAB) released topline results from its global Phase 3 GEMINI-1 trial of imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP) flares. Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session October 09, 2023 Via Benzinga Why Apellis Pharmaceuticals Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's Session July 31, 2023 Gainers Yellow Corporation (NASDAQ: YELL) shares jumped 106% to $1.46. The trucking company ceased operations on Sunday, according to a Wall Street Journal report. Via Benzinga Stocks That Hit 52-Week Lows On Monday July 24, 2023 On Monday morning, 70 companies achieved new lows for the year. Via Benzinga Stocks That Hit 52-Week Lows On Friday July 21, 2023 On Friday, 54 companies hit new 52-week lows. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023 May 22, 2023 Via Benzinga GSK Unveils Detailed Phase 3 Data For Jemperli In Frontline Endometrial Cancer Patients March 28, 2023 Via Benzinga Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session January 06, 2023 Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. Via Benzinga < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
